Dataset ID: 24
Dataset Details
Study Design
| Study Design Background |
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapies and high recurrence rates. The RNA aptamer sTN58 was developed to selectively bind TNBC cells and was found to target the membrane protein CD44, a key driver of tumor aggressiveness and stem-like behavior. By binding to CD44, sTN58 inhibits invasive growth and metastasis, showing strong tumor-targeting efficacy and therapeutic potential in orthotopic TNBC mouse models.
|
|---|---|
| Study Description |
Preclinical in vivo study evaluating the CD44-targeting RNA aptamer sTN58 for tumor localization and therapeutic efficacy in orthotopic triple-negative breast cancer mouse models.
|
| Study Type |
Preclinical in vivo imaging and therapeutic efficacy study
|
| Study Subtype |
In vivo
|
Publication
| Paper Linked |
Yes
|
|---|---|
| Paper Title |
A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth
|
| Paper Authors |
Caliendo Alessandra, Camorani Simona, Luis Exequiel Ibarra, Pinto Gabriella, Agnello Lisa, Albanese Sandra, Caianiello Antonietta, Illiano Anna, Festa Rosaria, Ambrosio Vincenzo, Scognamiglio Giosuè, Cantile Monica, Amoresano Angela, Fedele Monica, Zannetti Antonella, Cerchia Laura
|
| Affiliation |
Institute of Endotypes in Oncology, Metabolism and Immunology "Gaetano Salvatore", National Research Council, 80131, Naples, Italy Institute of Environmental Biotechnology and Health (INBIAS), National University of Rio Cuarto (UNRC), National Council for Scientific and Technological Research (CONICET), Río Cuarto, X5800BIA, Argentina Dipartimento di Scienze Chimiche Universit`a di Napoli Federico II, Consorzio Interuniversitario Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy Institute of Biostructures and Bioimaging, National Research Council, 80145, Naples, Italy Institutional Biobank-Scientific Directorate, National Cancer Institute INT-IRCCS Fondazione G. Pascale, 80131, Naples, Italy
|
| Paper Journal |
Bioactive Materials 50
|
| Paper Year |
2025
|
| Paper DOI | |
| Open Access |
Yes
|
Study Component
| Multi Modality Images |
No
|
|---|---|
| Imaging Modality |
OI
|
| Radiation |
No
|
| Imaging Coverage |
Tumor, liver, spleen, kidneys,lungs, heart, muscle
|
| Imaging Target |
Receptor acquisition
|
Dataset Information
| Institution |
Institute of Biostructures and Bioimaging, National Research Council
|
|---|---|
| PI |
Laura Cerchia
|
| Country Of Institution |
Italy
|
| Imaging Facility |
Prelinical Imaging Facility, Ceinge Biotecnologie Avanzate scarl
|
| Country Of Imaging Facility |
Italy
|
| Link To Dataset |
Internal server
|
| Funding |
No
|
| Dataset Access |
Limited
|
| DUO Data Use Permission | |
| DUO Data Use Modifier | |
| DUO Investigation | |
| Contact Person |
In Vivo Experimental Parameters
| Number Of Groups |
2
|
|---|---|
| Types Of Groups |
Treated group, control group
|
| Overall Sample Size |
6
|
| Main Disease Category |
Disease of cellular proliferation
|
| Specific Disease Model |
Cancer model
|
| Organ Or Tissue |
Mammary gland
|
| Sample Size For Each Group |
3 mice with NIR-sTN58, 3 mice NIR-SCR
|
| Randomization |
Yes
|
| Blinding |
Yes
|
| Species |
Mice
|
| Strain |
Balb/c
|
| Immune Status |
Immunocompetent
|
| Sex |
Female
|
| Age |
6 weeks old
|
| Weight |
20-22 grams
|
| Source Of Animals |
Charles River
|
Experimental Procedures
| Pharmacological Procedures Intervention And Control |
No
|
|---|---|
| Blood Sampling |
Yes
|
| Surgical Procedures Including Sham Surgery |
Yes
|
| Target Organ Tissue |
Mammary gland
|
| Pathogen Infection Intervention And Control |
No
|
| Analgesic Plan To Relieve Pain Suffering And Distress |
No
|
| Anesthesia For Imaging |
Yes
|
| Anesthesia Type |
Gas
|
| Anesthesia Drugs |
Isovet
|
| Anesthesia Dose |
Induction-3–4% isoflurane in O₂ ; Maintenance- 1–2% in O₂
|
| Euthanasia |
Yes
|
| Method |
Dislocation
|
| Histology |
Yes
|
| Tissues Collected Post Euthanasia |
Tumors, lungs
|
| Timing Of Collection |
The end of the experiment
|
| Imaging |
Yes
|
| Frequency Of Imaging |
4 time points (15min,1h, 3h, 24h)
|
| Timing Of Imaging |
Once tumor became 150 mm3
|
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule |
Yes
|
| Contrast Agent Chemical Drug |
NIR-sTN58
|
| Contrast Agent Dose |
0.75 nmol/100 μL
|
| Injection Volume |
100 μL
|
| Route Of Administration |
Intravenous
|
| Cell Lines |
Yes
|
| Cell Line |
4T1
|
Image Acquisition
| Instrument Vendor |
Perkin Elmer
|
|---|---|
| Instrument Type |
FMT 4000
|
| Image Acquisition Parameters |
Reflectance imaging (FRI) on the 750 nm channel
|
Image Data
| Image Type |
Processed image
|
|---|---|
| Image Scale |
Pmol
|
| Format Compression |
Fmt
|
| Dimensions |
2D/3D
|
| Ai Enhanced Algorithm |
No
|
Analyzed Data
| Data Used For Analysis |
Volume of interest and pmol
|
|---|---|
| Updated Year |
2025
|